REVIEW article
Front. Aging Neurosci.
Sec. Alzheimer's Disease and Related Dementias
Volume 17 - 2025 | doi: 10.3389/fnagi.2025.1646551
This article is part of the Research TopicAdvancing therapeutics for Alzheimer's disease and related dementias through multi-omics data analysis in ethnically diverse populationsView all 6 articles
Advancement in Modelling of Alzheimer's Disease: A Comprehensive Review of Preclinical Screening Platforms
Provisionally accepted
Souvik Adak
Shivam Singh*
Ridhi Jain
Abhilasha Tiwari
Binny SinghSumit Kumar
Ayushi DadhwalAvishek ChakrobortyAshish Kumar Sharma
Ravindra Pal SinghRajesh Kumar Sharma- Institute of Pharmacy, NIMS University, Jaipur, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Alzheimer's disease (AD) is a chronic and progressive neurodegenerative condition that worsens with time and causes memory loss and cognitive impairment. For prompt intervention and management of AD, early detection is essential. Screening models play a crucial role in identifying individuals at risk of developing AD before the onset of noticeable clinical symptoms. This review summarizes a wide range of in-vitro and in-vivo screening models currently utilized in AD research, highlighting their advantages and limitations. In-vitro systems-such as cell lines and primary neuronal cultures-provide controlled settings to investigate cellular mechanisms and drug efficacy. In contrast, in-vivo models, including transgenic rodents and other animals, better replicate the complex biological features of AD.Each model type comes with distinct benefits and limitations concerning clinical relevance, cost-effectiveness, and ethical challenges. By evaluating the utility and constrains of these models, this article seeks to assist researchers in choosing suitable platforms for preclinical investigations and support the advancement of improved diagnostic tools and therapeutic strategies for AD.
Keywords: Alzheimer's disease, cognitive impairment, APP, tau, Neurofibrillary Tangles, Screening models
Received: 13 Jun 2025; Accepted: 24 Jul 2025.
Copyright: © 2025 Adak, Singh, Jain, Tiwari, Singh, Kumar, Dadhwal, Chakroborty, Sharma, Singh and Sharma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shivam Singh, Institute of Pharmacy, NIMS University, Jaipur, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.